<?xml version="1.0" encoding="UTF-8"?><html>
   <div tagx="ui">s13063-015-0597-1</div>
   <div tagx="ji">1745-6215</div>
   <head>
      <div tagx="dochead">Study protocol</div>
      <div tagx="bibl">
         <div tagx="title">
            <p>The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated
               with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a
               randomised controlled trial
            </p>
         </div>
         <ul tagx="aug">
            <li tagx="au">
               <span tagx="snm">Okebe</span>
               <span tagx="fnm">Joseph</span>
               <span tagx="insr"></span>
               <a href="jokebe@mrc.gm">jokebe@mrc.gm</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Bousema</span>
               <span tagx="fnm">Teun</span>
               <span tagx="insr"></span>
               <a href="teun.Bousema@lshtm.ac.uk">teun.Bousema@lshtm.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Affara</span>
               <span tagx="fnm">Muna</span>
               <span tagx="insr"></span>
               <a href="maffara@mrc.gm">maffara@mrc.gm</a>
            </li>
            <li tagx="au">
               <span tagx="snm">DiTanna</span>
               <span tagx="fnm">GianLuca</span>
               <span tagx="insr"></span>
               <a href="GianLuca.DiTanna@lshtm.ac.uk">GianLuca.DiTanna@lshtm.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Eziefula</span>
               <span tagx="mi">C</span>
               <span tagx="fnm">Alice</span>
               <span tagx="insr"></span>
               <a href="chi.eziefula@lshtm.ac.uk">chi.eziefula@lshtm.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Jawara</span>
               <span tagx="fnm">Musa</span>
               <span tagx="insr"></span>
               <a href="mjawara@mrc.gm">mjawara@mrc.gm</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Nwakanma</span>
               <span tagx="fnm">Davis</span>
               <span tagx="insr"></span>
               <a href="dnwakanma@mrc.gm">dnwakanma@mrc.gm</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Amambua-Ngwa</span>
               <span tagx="fnm">Alfred</span>
               <span tagx="insr"></span>
               <a href="angwa@mrc.gm">angwa@mrc.gm</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Van geertruyden</span>
               <span tagx="fnm">Jean-Pierre</span>
               <span tagx="insr"></span>
               <a href="Jean-Pierre.VanGeertruyden@ua.ac.be">Jean-Pierre.VanGeertruyden@ua.ac.be</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Drakeley</span>
               <span tagx="fnm">Chris</span>
               <span tagx="insr"></span>
               <a href="Chris.Drakeley@lshtm.ac.uk">Chris.Drakeley@lshtm.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">D’Alessandro</span>
               <span tagx="fnm">Umberto</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="udalessandro@mrc.gm">udalessandro@mrc.gm</a>
            </li>
         </ul>
         <ul tagx="insg">
            <li tagx="ins">
               <p>Disease Control &amp; Elimination Theme, Medical Research Council Unit, Fajara, The Gambia</p>
            </li>
            <li tagx="ins">
               <p>Immunology and Infection Department, London School of Hygiene and Tropical Medicine,
                  London, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population
                  health, London School of Hygiene and Tropical Medicine, London, UK
               </p>
            </li>
            <li tagx="ins">
               <p>International Health Unit, Faculty of Medicine &amp; Health Sciences, University of Antwerp,
                  Antwerp, Belgium
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Disease Control, Faculty of Infectious and Tropical Diseases, London
                  School of Hygiene and Tropical Medicine, London, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Public health, Institute of Tropical Medicine, Antwerp, Belgium</p>
            </li>
         </ul>
         <span tagx="source">Trials</span>
         <span tagx="issn">1745-6215</span>
         <span tagx="pubdate">2015</span>
         <span tagx="volume">16</span>
         <span tagx="issue">1</span>
         <span tagx="fpage">70</span>
         <a href="http://www.trialsjournal.com/content/16/1/70">http://www.trialsjournal.com/content/16/1/70</a>
         <div tagx="xrefbib">
            <div tagx="pubidlist">
               <span tagx="pubid">10.1186/s13063-015-0597-1</span>
            </div>
         </div>
      </div>
      <div tagx="history">
         <span tagx="rec">
            <div tagx="date">
               <span tagx="day">3</span>
               <span tagx="month">10</span>
               <span tagx="year">2014</span>
            </div>
         </span>
         <span tagx="acc">
            <div tagx="date">
               <span tagx="day">10</span>
               <span tagx="month">2</span>
               <span tagx="year">2015</span>
            </div>
         </span>
         <span tagx="pub">
            <div tagx="date">
               <span tagx="day">1</span>
               <span tagx="month">3</span>
               <span tagx="year">2015</span>
            </div>
         </span>
      </div>
      <div tagx="cpyrt">
         <span tagx="year">2015</span>
         <div tagx="collab">Okebe et al.; licensee BioMed Central.</div>
         <div tagx="note">This is an Open Access article distributed under the terms of the Creative Commons
            Attribution License (
            <a href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided
            the original work is properly credited. The Creative Commons Public Domain Dedication
            waiver (
            <a href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated.
         </div>
      </div>
      <ul tagx="kwdg">
         <li tagx="kwd">Malaria</li>
         <li tagx="kwd">Plasmodium falciparum</li>
         <li tagx="kwd">Asymptomatic infection</li>
         <li tagx="kwd">Gametocyte</li>
         <li tagx="kwd">Primaquine</li>
         <li tagx="kwd">Safety</li>
         <li tagx="kwd">Efficacy</li>
         <li tagx="kwd">Elimination</li>
      </ul>
      <div id="abstract" tag="abstract">
         <div id="">
            <div tagx="st">
               <h2>Abstract</h2>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Background</h3>
               </div>
               <p>Finding efficacious tools to decrease and interrupt malaria transmission is essential
                  to sustain the gains in malaria control and contain the emergence of artemisinin resistance.
                  Primaquine is effective against 
                  <i>Plasmodium falciparum</i> gametocytes and recommended for treatment campaigns in (pre-)elimination settings.
                  Safety concerns preclude its use in endemic African countries with variable proportions
                  of glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. The efficacy of
                  the current recommended dose needs to be evaluated, particularly in individuals with
                  an asymptomatic malaria infection.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Methods/design</h3>
               </div>
               <p>This is a four-arm, open label, randomized controlled trial that aims to determine
                  and compare the effect of three different single doses of primaquine combined with
                  dihydroartemisinin-piperaquine, an artemisinin-based combination therapy, on gametocyte
                  carriage in asymptomatic, malaria infected, G6PD-normal individuals. Approximately
                  1,200 participants are enrolled and followed for 42 days, with the primary endpoint
                  being the prevalence of 
                  <i>Plasmodium falciparum</i> gametocyte carriage at day 7 of follow-up determined by quantitative nucleic acid
                  sequence based amplification assay. Direct membrane feeding experiments to determine
                  infectiousness to mosquitoes are conducted as a biological secondary endpoint.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Discussion</h3>
               </div>
               <p>Sub-Saharan Africa, with a relatively high but poorly characterized G6PD prevalence,
                  could potentially benefit from the use of primaquine to further reduce or interrupt
                  malaria transmission. However, G6PD screening may not be feasible given the cost and
                  difficulties in interpreting test results in terms of risk of haemolysis. Because
                  the haemolytic effect of primaquine is dose-dependent, determining the minimal gametocytocidal
                  and transmission-blocking dose of primaquine is extremely important to help address
                  public health concerns over its safety and validate the efficacy of lower than recommended
                  dosages. By including infectiousness to mosquitoes, the trial provides complementary
                  evidence for the potential of the drug to interrupt transmission to mosquitoes.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Trial registration</h3>
               </div>
               <p>ClinicalTrials.gov: 
                  <a href="NCT01838902">NCT01838902</a> (12 April 2013).
               </p>
            </div>
         </div>
      </div>
   </head>
   <div id="">
      <div tagx="st">
         <h2>Background</h2>
      </div>
      <p>The scale-up of anti-malaria interventions, including artemisinin-based combination
         therapy (ACT), and the subsequent decline in many malaria indicators has boosted prospects
         of local or regional malaria elimination 
         <span tagx="abbrgrp">
            <span tagx="abbr">1</span>
         </span>. However, it is evident that additional tools, including drugs effective against
         sexual (gametocyte) stages and programmes that are targeted at asymptomatic parasite
         carriage, would be needed if the goal of interrupting 
         <i>Plasmodium falciparum</i> malaria transmission were to be achieved.
      </p>
      <p>A number of endemic countries, including some in sub-Saharan Africa, have achieved
         substantial reductions in their malaria burden 
         <span tagx="abbrgrp">
            <span tagx="abbr">1</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">2</span>
         </span> and are considering the possibility of eliminating malaria within their borders.
         Artemisinin derivatives are extremely effective against both asexual and early-stage
         
         <i>P. falciparum</i> gametocytes and less so against mature gametocytes 
         <span tagx="abbrgrp">
            <span tagx="abbr">3</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">4</span>
         </span>. Combining ACTs with primaquine (PQ), an 8-aminoquinoline effective against mature
         gametocytes, targets all parasite stages and thus can halt the transfer of gametocytes
         from humans to mosquitoes. In this context, PQ could play an essential role in interrupting
         transmission but there are concerns, especially over its safety and efficacy, that
         could preclude its large-scale use in these countries.
      </p>
      <p>The optimal PQ dose used in combination with an ACT against 
         <i>P. falciparum</i> gametocytes has been the subject of some discussion. Previously recommended by the
         World Health Organization as a single 0.75 mg base/kg, it was recently revised to
         0.25 mg base/kg as this dose was unlikely to result in serious toxicity, especially
         in individuals with any glucose-6-phosphate dehydrogenase (G6PD) deficiency variant,
         while retaining its gametocytocidal effect 
         <span tagx="abbrgrp">
            <span tagx="abbr">5</span>
         </span>. Whereas the 0.75 mg base/kg PQ dose had a variable impact on transmission 
         <span tagx="abbrgrp">
            <span tagx="abbr">6</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">7</span>
         </span>, the efficacy of the 0.25 mg base/kg has not been evaluated in any recent trial.
      </p>
      <p>A recently concluded dose-ranging trial of PQ plus artemether-lumefantrine in children
         with uncomplicated malaria showed that a 0.4 mg/kg dose was as efficacious as the
         0.75 mg/kg dose in clearing gametocytes 
         <span tagx="abbrgrp">
            <span tagx="abbr">8</span>
         </span>. The trial excluded phenotypically G6PD-deficient individuals by fluorescent spot
         test and observed no clinically relevant haemolysis, although a statistically significant
         haemolytic effect was observed in phenotypically G6PD-sufficient but genotypically
         G6PD-deficient individuals receiving 0.75 mg/kg or 0.4 mg/kg PQ 
         <span tagx="abbrgrp">
            <span tagx="abbr">9</span>
         </span>.
      </p>
      <p>The dynamics of gametocyte carriage may differ considerably between symptomatic and
         asymptomatic infections and these differences in gametocyte dynamics may explain why
         previous studies in Africa have reached different conclusions on the added value of
         PQ in symptomatic and asymptomatic infections 
         <span tagx="abbrgrp">
            <span tagx="abbr">7</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">10</span>
         </span>. Although the acute phase of clinical malaria attacks have been associated with a
         subsequent wave of gametocytes that may persist longer after treatment 
         <span tagx="abbrgrp">
            <span tagx="abbr">11</span>
         </span>, asymptomatic individuals typically have lower densities of both asexual and sexual
         parasites yet potentially have more mature gametocytes as a result of the long duration
         of asymptomatic parasite carriage 
         <span tagx="abbrgrp">
            <span tagx="abbr">12</span>
         </span>. Because asymptomatic infections typically comprise the majority of malaria infections
         in populations 
         <span tagx="abbrgrp">
            <span tagx="abbr">13</span>
         </span>, studies in asymptomatic parasite carriers are needed to provide complementary evidence
         for the efficacy and safety of even lower PQ doses.
      </p>
      <p>This study combines gametocyte carriage measured using molecular detection methods
         
         <span tagx="abbrgrp">
            <span tagx="abbr">10</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">14</span>
         </span> with a complementary biological endpoint of gametocyte infectivity in a sub-group
         of study subjects to assess the transmission blocking effect of PQ 
         <span tagx="abbrgrp">
            <span tagx="abbr">15</span>
         </span>.
      </p>
      <div id="">
         <div tagx="st">
            <h3>Trial objectives and endpoints</h3>
         </div>
         <p>The trial aims to determine and compare the effect of three different single doses
            of PQ combined with an ACT, dihydroartemisinin-piperaquine (DHA-PPQ), on gametocyte
            carriage in asymptomatic, malaria-infected, G6PD-normal individuals. In addition,
            it will determine and compare the effect of the above combinations on change in haemoglobin
            concentration during follow-up, infectiousness to mosquitoes, parasite clearance time
            and cure rate.
         </p>
         <p>The main trial endpoint is the prevalence of 
            <i>P. falciparum</i> gametocyte carriage at day 7 of follow-up determined by quantitative nucleic acid
            sequence based amplification assay (QT-NASBA).
         </p>
         <p>Other endpoints include: 1) the prevalence of 
            <i>P. falciparum</i> gametocyte carriage, determined by QT-NASBA, during other follow-up visits; 2) change
            in haemoglobin values between enrollment (day 0) and each day of follow-up; 3) infectiousness
            to mosquitoes on day 7 determined by direct membrane feeding assay (DMFA); 4) proportion
            of participants with recurrent infections (polymerase chain reaction adjusted and
            unadjusted) after day 7; and 5) the prevalence of adverse events and serious adverse
            events.
         </p>
      </div>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Methods</h2>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Design</h3>
         </div>
         <p>This is a four-arm, open label, randomized controlled trial in which G6PD-normal asymptomatic
            
            <i>Plasmodium falciparum</i>-infected individuals identified through population screening are randomized to receive
            either a complete course of DHA-PPQ alone (control) or a course of DHA-PPQ plus one
            of three different doses of PQ (intervention): 0.75 mg base/kg, 0.4 mg base/kg and
            0.2 mg base/kg, given as a single dose.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Study area and participant selection</h3>
         </div>
         <p>Participants are recruited from villages around the Medical Research Council’s field
            stations in the Central and Upper River Regions in The Gambia. Malaria transmission
            in the country is well described, and characterized by marked seasonality with a peak
            between September and November 
            <span tagx="abbrgrp">
               <span tagx="abbr">16</span>
            </span>. Participants are selected in a two-stage screening process. An initial pre-screening
            is used to determine infection (rapid antigen test kit) and establish a baseline parasitaemia
            (microscopy). Individuals aged 1 year and above with parasite density ≥20 parasites/μl
            are invited to the base clinic the following day where, after a written informed consent,
            they undergo screening for G6PD status (N Dimopoulos SA, Greece), haemoglobin measurement
            (Hemocue, Ängelholm, Sweden) and, if eligible, are enrolled (Figure 
            <div tagx="figr">1</div>). Infected but ineligible persons are treated with a full course of artemether-lumefantrine.
            In addition, those with haemoglobin counts &lt;8 g/dl receive iron supplements while
            G6PD-deficient individuals will be counselled on their test results and provided with
            a notification card indicating their G6PD status which they are advised to present
            at clinics when seeking medical care.
            
         </p>
         <div tagx="fig">
            <div tagx="title">
               <p>Figure 1</p>
            </div>
            <caption>
               <p>DHA-PPQ, dihydroartemisinin-piperaquine; DMFA, direct membrane feeding assay; Hb,
                  haemoglobin; G6PD, glucose-6-phosphate dehydrogenase; PCR, polymerase chain reaction;
                  PQ, primaquine; RDT, rapid diagnostic test. 
               </p>
            </caption>
            <div tagx="text">
               <p>
                  <b>DHA-PPQ, dihydroartemisinin-piperaquine; DMFA, direct membrane feeding assay; Hb,
                     haemoglobin; G6PD, glucose-6-phosphate dehydrogenase; PCR, polymerase chain reaction;
                     PQ, primaquine; RDT, rapid diagnostic test.
                  </b>
               </p>
            </div>
            <div tagx="graphic"></div>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Randomisation and blinding</h3>
         </div>
         <p>Enrolment into the trial arms follows a randomisation scheme in a 1:1:1:1 ratio using
            blocks of varying size to ensure a balance in recruitment between the four groups.
            A randomisation list, generated by the trial statistician using Stata software version
            13 (Stata Corp. College Station, TX, USA), is sent to a physician not involved in
            the trial who puts the codes for the allocation groups into sequentially numbered,
            opaque envelopes. The envelopes are opened by the clinic team only after the potential
            participant meets the eligibility criteria.
         </p>
         <p>This is an open-label trial; staff involved in clinical care, including administering
            the trial drugs, are aware of the assigned groups but those involved in sample processing
            and data analysis are blinded.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Treatment and follow-up</h3>
         </div>
         <p>All participants in the trial will receive a complete 3-day course of DHA-PPQ based
            on body weight according to the manufacturer’s instructions. DHA-PPQ is available
            as both paediatric (dihydroartemisinin 20 mg/piperaquine 160 mg) and adult (dihydroartemisinin
            40 mg/piperaquine 320 mg) formulations. Participants in the three intervention arms
            are randomized to receive a single 0.75 mg/kg, 0.40 mg/kg or 0.20 mg/kg dose of PQ
            base on day 2 with the third dose of DHA-PPQ. Each tablet of PQ contains 15 mg base
            and, to ensure the accuracy of doses &lt;15 mg, the tablet will be reconstituted in 15 ml
            water to achieve a 1 mg/ml concentration and the required dose dispensed using a sterile
            syringe. A nurse directly observes all treatments and treatment may be repeated once
            if a participant vomits any of the drugs within 30 minutes of being administered.
         </p>
         <p>Each participant attends eight scheduled follow-up visits on days 3, 7, 10, 14, 21,
            28, 35, and 42 for clinical evaluation and blood sampling. Blood samples from a finger
            prick are collected for gametocyte (QT-NASBA) and asexual parasite clearance (microscopy
            and polymerase chain reaction) and haemoglobin measurement. Additional tests may be
            requested during unscheduled visits to the clinic (Table 
            <span tagx="tblr">1</span>). Thick blood films stained with 10% Giemsa for 10 minutes are examined under 1000-fold
            magnification by trained microscopists. Asexual parasite density is determined by
            counting the number of asexual parasites per white blood cell (WBC) until 500 WBCs
            have been counted (assuming a mean WBC count of 8,000/μl) and results presented as
            parasites/μl.
            
         </p>
         <table>
            <div tagx="title">
               <p>Table 1</p>
            </div>
            <caption>
               <p>
                  <b>Trial activity on scheduled visit days</b>
               </p>
            </caption>
            <tgroup>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <thead>
                  <tr>
                     <td>
                        <p>
                           <b>Day</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>−1</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>0</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>1</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>2</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>3</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>7</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>10</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>14</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>21</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>28</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>35</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>42</b>
                        </p>
                     </td>
                  </tr>
               </thead>
               <div tagx="tfoot">
                  <p>G6PD, glucose-6-phosphate dehydrogenase; PCR, polymerase chain reaction; QT-NASBA,
                     quantitative nucleic acid sequence based amplification assay; RDT, rapid diagnostic
                     test.
                  </p>
               </div>
               <tbody>
                  <tr>
                     <td>
                        <p>Village screening (RDT+ slide)</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                  </tr>
                  <tr>
                     <td>
                        <p>Informed consent for the trial</p>
                     </td>
                     <td></td>
                     <td>
                        <p>X</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                  </tr>
                  <tr>
                     <td>
                        <p>G6PD test</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                  </tr>
                  <tr>
                     <td>
                        <p>Clinical review (history and examination)</p>
                     </td>
                     <td></td>
                     <td>
                        <p>X</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Temperature, pulse</p>
                     </td>
                     <td></td>
                     <td>
                        <p>X</p>
                     </td>
                     <td></td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Weight</p>
                     </td>
                     <td></td>
                     <td>
                        <p>X</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                  </tr>
                  <tr>
                     <td>
                        <p>Thick blood film</p>
                     </td>
                     <td></td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Haemoglobin, PCR (filter paper)</p>
                     </td>
                     <td></td>
                     <td>
                        <p>X</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Gametocytaemia (QT-NASBA)</p>
                     </td>
                     <td></td>
                     <td>
                        <p>X</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td></td>
                     <td>
                        <p>X</p>
                     </td>
                     <td></td>
                     <td>
                        <p>X</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Adverse events</p>
                     </td>
                     <td></td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Treatment</p>
                     </td>
                     <td></td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td>
                        <p>X</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                  </tr>
                  <tr>
                     <td>
                        <p>Direct membrane feeding assay</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>X</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                  </tr>
               </tbody>
            </tgroup>
         </table>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Quantitative nucleic acid sequence based amplification assay</h3>
         </div>
         <p>The primary endpoint of the trial is the prevalence of gametocytes measured by molecular
            methods on day 7 of follow-up. The detection and quantification of gametocytes is
            by real-time QT-NASBA which is based on stage-specific gene expression of Pfs25 mRNA
            by parasites. QT-NASBA is a high throughput technique suited to detecting mature gametocytes
            with a sensitivity of 0.01 to 0.1 gametocytes/μl blood 
            <span tagx="abbrgrp">
               <span tagx="abbr">17</span>
            </span>. It is based on the activities of three enzymes: Reverse transcriptase, T7 RNA polymerase
            and RNase H and target-specific forward and reverse primers, which includes a T7 polymerase
            promoter sequence, for continuous and direct amplification of RNA molecules in a single
            mixture at an isothermal temperature of 41°C. Real-time gametocyte detection and quantification
            is by a fluorescent-labelled molecular beacon with a sequence complementary to those
            of amplified anti-sense RNA molecules.
         </p>
         <p>RNA is extracted manually from 50 μl of blood stored in RNAlater using commercial
            lysis buffers (Severn Biotech, Kidderminster, Worcestershire, UK) and previously described
            methods that involve nuclease inactivation and nucleic acid binding 
            <span tagx="abbrgrp">
               <span tagx="abbr">18</span>
            </span>. Gametocyte density is calculated in relation to the standard gametocyte stage V
            dilution series using the time point of amplification at which the fluorescence detecting
            target amplicons exceed the mean fluorescence of three negative controls + 20 standard
            deviations 
            <span tagx="abbrgrp">
               <span tagx="abbr">17</span>
            </span>. Standard curves for density quantification are generated using trend lines of known
            quantities of gametocytes from laboratory-cultured NF54 parasite strains.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Direct membrane feeding assay</h3>
         </div>
         <p>To measure biological evidence of gametocyte clearance, a subset of 100 participants
            from each arm will be randomly selected for direct membrane feeding experiments on
            day 7 using a published protocol 
            <span tagx="abbrgrp">
               <span tagx="abbr">19</span>
            </span>. In summary, 3 ml of blood are collected from the participant’s arm and 500 μl is
            added to two glass feeders and fed to about 100 locally reared 4- to 5-day-old female
            
            <i>Anopheles gambiae sensu stricto</i> mosquitoes through an artificial membrane. The setup is maintained at 37°C by a temperature
            controlled water bath and, after 15 minutes of feeding, fully fed mosquitoes are transferred
            into a holding cage maintained at 27 to 29°C and sustained on 5% glucose for 7 days
            while partially fed and unfed ones are destroyed. Mosquitoes that survive to this
            period are dissected in 0.5% mercurochrome, and their midguts examined for oocyst
            prevalence and density. The proportion of infected mosquitoes, the number of infected
            mosquitoes divided by the total number of examined mosquitoes, and the density of
            oocysts in infected mosquitoes is presented.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Sample size considerations</h3>
         </div>
         <p>The sample size was calculated to detect a difference in gametocyte prevalence on
            day 7 after treatment, between the control (DHA-PPQ only) and 0.75 mg/kg PQ arm, and
            between this and lower doses of PQ (0.4 mg/kg and 0.2 mg/kg). Two hypotheses underscore
            the sample size calculation: 1) treatment with PQ (any dose) and DHA-PPQ results in
            significantly lower gametocyte carriage compared to treatment with DHA-PPQ alone;
            and 2) a single dose of 0.4 mg base/kg or 0.2 mg base/kg PQ administered with the
            last dose of DHA-PPQ has similar gametocytocidal efficacy as a single 0.75 mg base/kg
            dose.
         </p>
         <p>For the first hypothesis, the underlying assumption is that, although a substantial
            proportion of asymptomatic carriers also carry gametocytes 
            <span tagx="abbrgrp">
               <span tagx="abbr">20</span>
            </span>, treatment with an ACT alone would reduce gametocyte prevalence on day 7 to around
            18%, and the addition of PQ at 0.75 mg/kg will further reduce the prevalence by 50%
            (that is, to 9%). A sample size of 300 participants per arm would have 90% power to
            detect this difference, at the 5% significance level, allowing for 10% of enrolees
            being non-compliant or lost to follow-up.
         </p>
         <p>In the second hypothesis, assuming a prevalence of 9% in the standard PQ arm, 300
            participants would be sufficient, with 90% power, to detect a confidence interval
            around the prevalence in the lower dose PQ arm below 16% and 80% power to detect that
            this confidence interval is entirely below 15%.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Statistical analysis plan</h3>
         </div>
         <p>Analysis of efficacy will be on the basis of intention-to-treat. Gametocyte densities
            will be compared between treatment groups using one-way analysis of variance on log-transformed
            gametocyte densities; gametocyte carriage during follow-up will be estimated by calculating
            for each arm the area under the curve (AUC) of both the gametocyte density and gametocyte
            prevalence against time. The AUC between treatment groups will be compared using non-parametric
            tests. The Kaplan-Meier estimator will be used to compare gametocyte clearance times
            between study arms for individuals who are gametocyte positive by QT-NASBA at enrolment.
         </p>
         <p>For the non-inferiority comparison between the PQ arms, the 95% confidence around
            the gametocyte prevalence in the PQ 0.4/0.2 mg/kg arms at day 7 will be compared to
            the non-inferiority limit determined by the prevalence in the PQ 0.75 mg/kg arm and
            delta.
         </p>
         <p>For the DMFA, the proportion of infectious individuals will be compared between arms
            using chi-squared statistics. The proportion of infected mosquitoes will be compared
            between groups using mixed models to account for clustering within cages fed on blood
            from the same individual.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Data entry and validation</h3>
         </div>
         <p>Clinical data will be captured from pre-tested medical records and relevant fields
            entered onto an electronic case report form base created in Openclinica (OpenClinica
            LLC, Waltham, Ma, USA). Data will be single entered with source-data verification
            done for each entry. Laboratory-generated (DMFA and QT-NASBA) data will be double
            entered onto a Microsoft Access database (Microsoft Corp., Richmond, WA, USA) and
            linked to the clinical data after validation.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Ethical approval</h3>
         </div>
         <p>The trial was approved by The Gambia Government/MRC Joint Ethics Committee (SCC 1321)
            on 13 March 2013.
         </p>
      </div>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Discussion</h2>
      </div>
      <p>Local and regional malaria elimination is gaining acceptance as a means to sustain
         the gains made in reducing the malaria burden and limiting/preventing the spread of
         artemisinin resistance. However, achieving these objectives would require a fresh
         perspective on the necessary tools and applications.
      </p>
      <p>Although individuals with clinical disease due to asexual 
         <i>P. falciparum</i> infection also carry gametocytes in variable amounts 
         <span tagx="abbrgrp">
            <span tagx="abbr">21</span>
         </span>, asymptomatic infections are believed to play an important role across all levels
         of malaria transmission and therefore targeting only clinical cases would miss the
         large human reservoir of infection 
         <span tagx="abbrgrp">
            <span tagx="abbr">12</span>
         </span>. This concept is supported by evidence from empirical studies and mathematical models
         
         <span tagx="abbrgrp">
            <span tagx="abbr">22</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">23</span>
         </span>, and the combination of an ACT with PQ is recommended in places where (pre-)elimination
         is being considered 
         <span tagx="abbrgrp">
            <span tagx="abbr">24</span>
         </span>.
      </p>
      <p>In asymptomatic infections, parasite density (both asexual forms and gametocytes)
         are much lower than in clinical cases. However, one model estimate predicts that these
         low-density infections, even when undetectable by microscopy, may still be infectious
         to mosquitoes 
         <span tagx="abbrgrp">
            <span tagx="abbr">25</span>
         </span>. Parasite densities are estimated by counting parasites against a given number of
         WBCs, usually 200 WBCs, and then assuming 8,000 WBCs per μl 
         <span tagx="abbrgrp">
            <span tagx="abbr">26</span>
         </span>. Nevertheless, when parasite densities are &lt;100/μl, a higher sensitivity may be needed
         
         <span tagx="abbrgrp">
            <span tagx="abbr">26</span>
         </span> and this can be done by increasing the number of WBCs against which the number of
         parasites are counted, usually 500. Given the short time available to recruit participants
         into the trial, counting parasites against 500 WBCs is extremely challenging.
      </p>
      <p>As the trial aims to determine the lowest gametocytocidal PQ dose, it was necessary
         to include individuals with microscopically detectable infections. The threshold of
         &gt;20 parasites/μl as an inclusion criterion was chosen as a proxy to increase the likelihood
         for gametocytaemia 
         <span tagx="abbrgrp">
            <span tagx="abbr">11</span>
         </span>. Including carriers of submicroscopic infection would not have been feasible given
         the need to determine their eligibility in a relatively short time. Blood slides can
         be re-read later and the number of WBCs per slide increased for higher sensitivity
         
         <span tagx="abbrgrp">
            <span tagx="abbr">27</span>
         </span>.
      </p>
      <p>The potential for inducing haemolysis is probably the main reservation for the widespread
         use of PQ. In sub-Saharan Africa, the overall prevalence of G6PD deficiency is considered
         to be high 
         <span tagx="abbrgrp">
            <span tagx="abbr">28</span>
         </span>. A recent survey in The Gambia showed that the prevalence of the 202A- mutation,
         reportedly the most common in sub-Saharan Africa, was 1.8% while the phenotype prevalence
         was 6.4% overall; 7.8% in males and 4.9% in females 
         <span tagx="abbrgrp">
            <span tagx="abbr">29</span>
         </span>. Such low numbers may suggest a low risk but does not eliminate it entirely as individuals
         with “normal” G6PD status have developed haemolysis 
         <span tagx="abbrgrp">
            <span tagx="abbr">30</span>
         </span>. A trial to evaluate the tolerability and safety of increasing doses of PQ in combination
         with an ACT in G6PD-deficient males with an asymptomatic 
         <i>P. falciparum</i> malaria infection has recently been initiated (NCT02174900) and the results would
         complement those of this trial.
      </p>
      <p>As the haemolytic effect of PQ is dose-dependent, determining the minimal gametocytocidal
         dose is considered an extremely important first step in addressing public health concerns
         related to the safety and efficacy of PQ as summarized in a recent systematic review
         
         <span tagx="abbrgrp">
            <span tagx="abbr">31</span>
         </span>. Since the initial trial protocol was developed, a single 0.25 mg base/kg dose of
         PQ combined with an ACT is now recommended as sufficiently safe and gametocytocidal
         to be used without screening for G6PD deficiency 
         <span tagx="abbrgrp">
            <span tagx="abbr">5</span>
         </span>. However, the evidence for this dose may be considered inadequate by contemporary
         standards.
      </p>
      <p>The optimization of the PQ dosing regimen therefore represents an important knowledge
         gap and research priority 
         <span tagx="abbrgrp">
            <span tagx="abbr">32</span>
         </span> as it provides a “new/old” tool for malaria (pre-)elimination. The recently concluded
         dose-finding trial in children aged 1 to 10 years with uncomplicated falciparum malaria
         and normal G6PD enzyme function provides encouraging complementary information to
         support research in G6PD-deficient individuals 
         <span tagx="abbrgrp">
            <span tagx="abbr">8</span>
         </span>. Also, the haematological consequences may be less manifest in asymptomatic carriers
         as the malaria-related haemolysis would be less pronounced.
      </p>
      <p>By evaluating infectiousness to mosquitoes, the trial contributes a biological endpoint
         - the evidence for transmission reduction or complete transmission blockade to mosquitoes
         that is ultimately relevant for public health policy making.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Trial status</h2>
      </div>
      <p>Recruitment started in August 2013 with trial results expected in December 2015.</p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Abbreviations</h2>
      </div>
      <p>ACT: artemisinin-based combination therapy</p>
      <p>AUC: area under the curve</p>
      <p>DHA-PPQ: dihydroartemisinin-piperaquine</p>
      <p>DMFA: direct membrane feeding assay</p>
      <p>G6PD: glucose-6-phosphate dehydrogenase</p>
      <p>PQ: primaquine</p>
      <p>QT-NASBA: quantitative nucleic acid sequence based amplification assay</p>
      <p>WBC: white blood cell</p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Competing interests</h2>
      </div>
      <p>The authors declare that they have no competing interests.</p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Authors’ contributions</h2>
      </div>
      <p>UDA conceived the study and wrote the trial protocol. JO contributed to the protocol
         design, wrote the draft manuscript and coordinated the trial activities. CD and TB
         developed the protocol for membrane feeding and contributed to the trial protocol
         design. TB, MA, AAN and DN developed and tested the protocols for laboratory assays
         used in the trial. GLDT wrote the statistical analysis plan and reviewed the sample
         size calculations. ACE contributed to the design of the trial. MJ contributed to developing
         the membrane feeding protocol. UDA and JPVG contributed to the writing and review
         of the manuscript. All authors read and reviewed the manuscript, and approved the
         final manuscript.
      </p>
   </div>
   <div tagx="bm">
      <div tagx="ack">
         <div id="">
            <div tagx="st">
               <h2>Acknowledgements</h2>
            </div>
            <p>The authors acknowledge Mathurin Diatta and Abdoulaye Gaye for setting up the membrane
               feeding experiments, Drs Edgard Dabira and Frank Sanya-Isijola for drafting the standard
               operating procedures and supervising the field teams, and Henry Badji for supervising
               laboratory activities. CD and TB are supported by a grant from the Bill &amp; Melinda
               Gates Foundation (AFIRM, grant number OPP1034789). The trial is jointly funded under
               the Global Health Trials Scheme by the Medical Research Council (UK), the Department
               for International Development (DFID) and the Wellcome Trust. The funders have no role
               in the trial design or the preparation of the protocol or manuscript.
            </p>
         </div>
      </div>
      <div tagx="refgrp">
         <div tagx="bibl">
            <div tagx="title">
               <p>Changes in the burden of malaria in sub-Saharan Africa</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">O’Meara</span>
                  <span tagx="fnm">WP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mangeni</span>
                  <span tagx="fnm">JN</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Steketee</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Greenwood</span>
                  <span tagx="fnm">B</span>
               </li>
            </ul>
            <span tagx="source">Lancet Infect Dis</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">10</span>
            <span tagx="fpage">545</span>
            <span tagx="lpage">55</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/S1473-3099(10)70096-7</span>
                  <span tagx="pubid">20637696</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Continued decline of malaria in The Gambia with implications for elimination</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Ceesay</span>
                  <span tagx="fnm">SJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Casals-Pascual</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Nwakanma</span>
                  <span tagx="fnm">DC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Walther</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gomez-Escobar</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Fulford</span>
                  <span tagx="fnm">AJ</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">PLoS One</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">5</span>
            <span tagx="fpage">e12242</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1371/journal.pone.0012242</span>
                  <span tagx="pubid">20805878</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>A research agenda for malaria eradication: drugs</p>
            </div>
            <ul tagx="insg">
               <li tagx="ins">
                  <p>malERA Consultative Group on Drugs</p>
               </li>
            </ul>
            <span tagx="source">PLoS Med</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">8</span>
            <span tagx="fpage">e1000402</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1371/journal.pmed.1000402</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The role of antimalarial treatment in the elimination of malaria</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Gosling</span>
                  <span tagx="fnm">RD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Okell</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mosha</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Chandramohan</span>
                  <span tagx="fnm">D</span>
               </li>
            </ul>
            <span tagx="source">Clin Microbiol Infect</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">17</span>
            <span tagx="fpage">1617</span>
            <span tagx="lpage">23</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1111/j.1469-0691.2011.03660.x</span>
                  <span tagx="pubid">21951597</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide
                  in populations where G6PD deficiency is common
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">White</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Qiao</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Qi</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Luzzatto</span>
                  <span tagx="fnm">L</span>
               </li>
            </ul>
            <span tagx="source">Malar J</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">11</span>
            <span tagx="fpage">418</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1186/1475-2875-11-418</span>
                  <span tagx="pubid">23237606</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>A cluster-randomized trial of mass drug administration with a gametocytocidal drug
                  combination to interrupt malaria transmission in a low endemic area in Tanzania
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Shekalaghe</span>
                  <span tagx="fnm">SA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Drakeley</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">van den Bosch</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">ter Braak</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">van den Bijllaardt</span>
                  <span tagx="fnm">W</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mwanziva</span>
                  <span tagx="fnm">C</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Malar J</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">10</span>
            <span tagx="fpage">247</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1186/1475-2875-10-247</span>
                  <span tagx="pubid">21864343</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>A randomized open-label trial of artesunate-sulfadoxine-pyrimethamine with or without
                  primaquine for elimination of sub-microscopic P falciparum parasitaemia and gametocyte
                  carriage in eastern Sudan
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">El-Sayed</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">El-Zaki</span>
                  <span tagx="fnm">SE</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Babiker</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gadalla</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ageep</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mansour</span>
                  <span tagx="fnm">F</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">PLoS One</span>
            <span tagx="pubdate">2007</span>
            <span tagx="volume">2</span>
            <span tagx="fpage">e1311</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1371/journal.pone.0001311</span>
                  <span tagx="pubid">18074034</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children
                  with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging
                  trial
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Eziefula</span>
                  <span tagx="fnm">AC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bousema</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Yeung</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kamya</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Owaraganise</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gabagaya</span>
                  <span tagx="fnm">G</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Lancet Infect Dis</span>
            <span tagx="pubdate">2014</span>
            <span tagx="volume">14</span>
            <span tagx="fpage">130</span>
            <span tagx="lpage">9</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/S1473-3099(13)70268-8</span>
                  <span tagx="pubid">24239324</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Glucose-6-phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum-infected
                  African children receiving single-dose primaquine
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Eziefula</span>
                  <span tagx="fnm">AC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pett</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Grignard</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Opus</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kiggundu</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kamya</span>
                  <span tagx="fnm">MR</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Antimicrob Agents Chemother</span>
            <span tagx="pubdate">2014</span>
            <span tagx="volume">58</span>
            <span tagx="fpage">4971</span>
            <span tagx="lpage">3</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1128/AAC.02889-14</span>
                  <span tagx="pubid">24913169</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after
                  treatment with sulphadoxine-pyrimethamine and artesunate
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Shekalaghe</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Drakeley</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gosling</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ndaro</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">van Meegeren</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Enevold</span>
                  <span tagx="fnm">A</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">PLoS One</span>
            <span tagx="pubdate">2007</span>
            <span tagx="volume">2</span>
            <span tagx="fpage">e1023</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1371/journal.pone.0001023</span>
                  <span tagx="pubid">17925871</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Gametocytaemia after drug treatment of asymptomatic plasmodium falciparum</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Dunyo</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Milligan</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Edwards</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sutherland</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Targett</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pinder</span>
                  <span tagx="fnm">M</span>
               </li>
            </ul>
            <span tagx="source">PLoS Clin Trials</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">1</span>
            <span tagx="fpage">20</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1371/journal.pctr.0010020</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Estimates of the infectious reservoir of Plasmodium falciparum malaria in The Gambia
                  and in Tanzania
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Drakeley</span>
                  <span tagx="fnm">CJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Akim</span>
                  <span tagx="fnm">NI</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sauerwein</span>
                  <span tagx="fnm">RW</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Greenwood</span>
                  <span tagx="fnm">BM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Targett</span>
                  <span tagx="fnm">GA</span>
               </li>
            </ul>
            <span tagx="source">Trans R Soc Trop Med Hyg</span>
            <span tagx="pubdate">2000</span>
            <span tagx="volume">94</span>
            <span tagx="fpage">472</span>
            <span tagx="lpage">6</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/S0035-9203(00)90056-7</span>
                  <span tagx="pubid">11132369</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The silent threat: asymptomatic parasitemia and malaria transmission</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Lindblade</span>
                  <span tagx="fnm">KA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Steinhardt</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Samuels</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kachur</span>
                  <span tagx="fnm">SP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Slutsker</span>
                  <span tagx="fnm">L</span>
               </li>
            </ul>
            <span tagx="source">Expert Rev Anti Infect Ther</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">11</span>
            <span tagx="fpage">623</span>
            <span tagx="lpage">39</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1586/eri.13.45</span>
                  <span tagx="pubid">23750733</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Evaluation of Plasmodium falciparum gametocyte detection in different patient material</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Kast</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Berens-Riha</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zeynudin</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Abduselam</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Eshetu</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Loscher</span>
                  <span tagx="fnm">T</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Malar J</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">12</span>
            <span tagx="fpage">438</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1186/1475-2875-12-438</span>
                  <span tagx="pubid">24305630</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The role of anti-malarial drugs in eliminating malaria</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">White</span>
                  <span tagx="fnm">N</span>
               </li>
            </ul>
            <span tagx="source">Malar J</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">7</span>
            <span tagx="fpage">S8</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1186/1475-2875-7-S1-S8</span>
                  <span tagx="pubid">19091042</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Ceesay</span>
                  <span tagx="fnm">SJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Casals-Pascual</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Erskine</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Anya</span>
                  <span tagx="fnm">SE</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Duah</span>
                  <span tagx="fnm">NO</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Fulford</span>
                  <span tagx="fnm">AJ</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Lancet</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">372</span>
            <span tagx="fpage">1545</span>
            <span tagx="lpage">54</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/S0140-6736(08)61654-2</span>
                  <span tagx="pubid">18984187</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>To assess whether indoor residual spraying can provide additional protection against
                  clinical malaria over current best practice of long-lasting insecticidal mosquito
                  nets in The Gambia: study protocol for a two-armed cluster-randomised trial
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Pinder</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Jawara</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Jarju</span>
                  <span tagx="fnm">LB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kandeh</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Jeffries</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lluberas</span>
                  <span tagx="fnm">MF</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Trials</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">12</span>
            <span tagx="fpage">147</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1186/1745-6215-12-147</span>
                  <span tagx="pubid">21663656</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Plasmodium falciparum gametocytes in Gambian adults</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Drakeley</span>
                  <span tagx="fnm">CJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Flobbe</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Greenwood</span>
                  <span tagx="fnm">BM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Targett</span>
                  <span tagx="fnm">GA</span>
               </li>
            </ul>
            <span tagx="source">Ann Trop Med Parasitol</span>
            <span tagx="pubdate">2000</span>
            <span tagx="volume">94</span>
            <span tagx="fpage">399</span>
            <span tagx="lpage">401</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10945050</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">Ouédraogo AL, Guelbéogo WM, Cohuet A, Morlais I, King JG, Gonçalves BP, et al. Methodology:
               a protocol for membrane feeding assays to determine the infectiousness of P. falciparum
               naturally infected individuals to Anopheles gambiae. Malaria World J. 2013;4.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Age-dependent distribution of Plasmodium falciparum gametocytes quantified by Pfs25
                  real-time QT-NASBA in a cross-sectional study in Burkina Faso
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Ouedraogo</span>
                  <span tagx="fnm">AL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schneider</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">de Kruijf</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Nebie</span>
                  <span tagx="fnm">I</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Verhave</span>
                  <span tagx="fnm">JP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cuzin-Ouattara</span>
                  <span tagx="fnm">N</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Am J Trop Med Hyg</span>
            <span tagx="pubdate">2007</span>
            <span tagx="volume">76</span>
            <span tagx="fpage">626</span>
            <span tagx="lpage">30</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">17426160</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection
                  methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal
                  drugs
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Bousema</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Okell</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Shekalaghe</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Griffin</span>
                  <span tagx="fnm">JT</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Omar</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sawa</span>
                  <span tagx="fnm">P</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Malar J</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">9</span>
            <span tagx="fpage">136</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1186/1475-2875-9-136</span>
                  <span tagx="pubid">20497536</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Song</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Socheat</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Tan</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dara</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Deng</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sokunthea</span>
                  <span tagx="fnm">S</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Malar J</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">9</span>
            <span tagx="fpage">57</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1186/1475-2875-9-57</span>
                  <span tagx="pubid">20175930</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission
                  in low endemicity Thai-Myanmar border populations
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Lawpoolsri</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Klein</span>
                  <span tagx="fnm">EY</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Singhasivanon</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Yimsamran</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Thanyavanich</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Maneeboonyang</span>
                  <span tagx="fnm">W</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Malar J</span>
            <span tagx="pubdate">2009</span>
            <span tagx="volume">8</span>
            <span tagx="fpage">159</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1186/1475-2875-8-159</span>
                  <span tagx="pubid">19604346</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <ul tagx="insg">
               <li tagx="ins">
                  <p>World Health Organization</p>
               </li>
            </ul>
            <span tagx="source">Guidelines for the Treatment of Malaria</span>
            <div tagx="publisher">World Health Organization, Geneva</div>
            <div tagx="edition">2</div>
            <span tagx="pubdate">2010</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Predicting mosquito infection from Plasmodium falciparum gametocyte density and estimating
                  the reservoir of infection
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Churcher</span>
                  <span tagx="fnm">TS</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bousema</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Walker</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Drakeley</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schneider</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ouédraogo</span>
                  <span tagx="fnm">AL</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">eLife</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">2</span>
            <span tagx="fpage">e00626</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.7554/eLife.00626</span>
                  <span tagx="pubid">23705071</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <ul tagx="insg">
               <li tagx="ins">
                  <p>World Health Organization</p>
               </li>
            </ul>
            <span tagx="source">Malaria Microscopy Quality Assurance Manual, vol. 1</span>
            <div tagx="publisher">World Health Organization, Geneva</div>
            <span tagx="pubdate">2008</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Asymptomatic malaria infections: detectability, transmissibility and public health
                  relevance
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Bousema</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Okell</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Felger</span>
                  <span tagx="fnm">I</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Drakeley</span>
                  <span tagx="fnm">C</span>
               </li>
            </ul>
            <span tagx="source">Nat Rev Microbiol</span>
            <span tagx="pubdate">2014</span>
            <span tagx="volume">12</span>
            <span tagx="fpage">833</span>
            <span tagx="lpage">40</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1038/nrmicro3364</span>
                  <span tagx="pubid">25329408</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>G6PD deficiency prevalence and estimates of affected populations in malaria endemic
                  countries: a geostatistical model-based map
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Howes</span>
                  <span tagx="fnm">RE</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Piel</span>
                  <span tagx="fnm">FB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Patil</span>
                  <span tagx="fnm">AP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Nyangiri</span>
                  <span tagx="fnm">OA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gething</span>
                  <span tagx="fnm">PW</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dewi</span>
                  <span tagx="fnm">M</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">PLoS Med</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">9</span>
            <span tagx="fpage">e1001339</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1371/journal.pmed.1001339</span>
                  <span tagx="pubid">23152723</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The prevalence of glucose-6-phosphate dehydrogenase deficiency in Gambian school children</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Okebe</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Amambua-Ngwa</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Parr</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Nishimura</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Daswani</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Takem</span>
                  <span tagx="fnm">EN</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Malar J</span>
            <span tagx="pubdate">2014</span>
            <span tagx="volume">13</span>
            <span tagx="fpage">148</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1186/1475-2875-13-148</span>
                  <span tagx="pubid">24742291</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin
                  is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Shekalaghe</span>
                  <span tagx="fnm">SA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">ter Braak</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Daou</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kavishe</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">van den Bijllaardt</span>
                  <span tagx="fnm">W</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">van den Bosch</span>
                  <span tagx="fnm">S</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Antimicrob Agents Chemother</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">54</span>
            <span tagx="fpage">1762</span>
            <span tagx="lpage">8</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1128/AAC.01135-09</span>
                  <span tagx="pubid">20194698</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Primaquine for reducing Plasmodium falciparum transmission</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Graves</span>
                  <span tagx="fnm">PM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gelband</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Garner</span>
                  <span tagx="fnm">P</span>
               </li>
            </ul>
            <span tagx="source">Cochrane Database Syst Rev</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">9</span>
            <div tagx="note">Article ID CD008152</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">22972117</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">A research agenda for malaria eradication: drugs. PLoS Med. 2011;8:e1000402.</div>
         </div>
      </div>
   </div>
</html>